

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

SSL0064

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/511886INTERNATIONAL APPLICATION NO.
PCT/FR03/01232INTERNATIONAL FILING DATE
17 April 2003PRIORITY DATE CLAIMED
19 April 2002TITLE OF INVENTION: *N*-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy


APPLICANT(S) FOR DO/EO/US: DARGAZANLI, Gihad, ESTENNE-BOUHTOU, Geneviève, MAGAT, Pascale, MARABOUT, Benoît, MEDAISKO, Florence, ROGER, Pierre, SEVRIN, Mireille, VERONIQUE, Corrine

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application.
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An executed oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
Citation of References
Information Disclosure Statement by Applicant (Form PTO-1449)

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/511886		INTERNATIONAL APPLICATION NO. PCT/FR03/01232		ATTORNEY'S DOCKET NUMBER SSL0064	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international Search Report not prepared by the EPO or JPO \$1110.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$950.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .. \$790.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$750.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 950.00</div>				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20	0	x \$18.00	\$ 950.00	
Independent claims	1 - 3 =	0	x \$88.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$300.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 950.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 950.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$	
TOTAL NATIONAL FEE =				\$ 950.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 950.00	
				Amount to be refunded:	\$
				Charged	\$950.00
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>19-0091</u> in the amount of <u>\$950.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0091</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Patent Department		27546 PATENT TRADEMARK OFFICE		<div style="text-align: center;">  SIGNATURE </div> <div style="text-align: right;"> DATE <u>October 19, 2004</u> </div>	
Sanofi-Synthelabo Inc.				Michael D. Alexander	
9 Great Valley Parkway				NAME	
P.O. Box 3026				36,080	
Malvern, PA 19355				REGISTRATION NUMBER	
Facsimile: (610) 889-8799				(610) 889-8802	
				TELEPHONE NUMBER	

10/511886

DT01 Rec'd PCT/PTC 19 OCT 2004

ENGLISH TRANSLATION OF INTERNATIONAL PATENT

APPLICATION PCT/FR03/01232

filed on 17 April 2003

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EV 525096480 US

Date of Deposit: October 19, 2004

I hereby certify that the attached English Translation is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to:

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Jon Hylenski
Signature

10/511886

1 Rec'd PCT/PTO 19 OCT 2004

Application of: DARGAZANLI, Gihad, ESTENNE-BOUHTOU, Geneviève,
MAGAT, Pascale, MARABOUT, Benoît, MEDAISKO, Florence,
ROGER, Pierre, SEVRIN, Mireille, VERONIQUE, Corrine

Docket No.: SSL0064

Filing Under 35 U.S.C. § 371

Filed As a U.S. National Phase Application of
International Application No. PCT/FR03/01232
Filed 17 April 2003

FOR: N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their
preparation and their application in therapy

CERTIFICATE UNDER 37 C.F.R. 1.10

Express Mail Label No.: EV 525096480 US

Date of Deposit: October 19, 2004

I hereby certify that this paper is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" Service on the
date indicated above, and is addressed to: Mail Stop PCT,

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


Signature